Atlas Trials

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Clinical trial NCT05439499 · UNKNOWN

Trial details

NCT number
NCT05439499
Sponsor
Ahon Pharmaceutical Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced Breast CancerFemale Breast Cancer
Start date
2022-03-02
Primary completion
2024-09-20
Enrollment
434

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.